TABLE OF CONTENTS
Volume 22, Issue 7 (July 2008)
Spotlight Reviews
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal FREE
A M Vannucchi, E Antonioli, P Guglielmelli, A Pardanani and A Tefferi
Leukemia 22: 1299-1307; advance online publication, May 22, 2008; doi:10.1038/leu.2008.113
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features FREE
A Orazi and U Germing
Leukemia 22: 1308-1319; advance online publication, May 15, 2008; doi:10.1038/leu.2008.119
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders FREE
C Walz, N C P Cross, R A Van Etten and A Reiter
Leukemia 22: 1320-1334; advance online publication, June 5, 2008; doi:10.1038/leu.2008.133
Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia FREE
P D Emanuel
Leukemia 22: 1335-1342; advance online publication, June 12, 2008; doi:10.1038/leu.2008.162
Treatment of plasma cell dyscrasias with lenalidomide FREE
M A Dimopoulos, E Kastritis and S V Rajkumar
Leukemia 22: 1343-1353; advance online publication, May 29, 2008; doi:10.1038/leu.2008.123
Original Articles
Molecular Targets for Therapy
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells
M MacPartlin, A M Smith, B J Druker, L A Honigberg and M W Deininger
Leukemia 22: 1354-1360; advance online publication, June 12, 2008; doi:10.1038/leu.2008.126
Acute Leukemias
Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications?
A Rabbat, D Chaoui, A Lefebvre, N Roche, O Legrand, C Lorut, B Rio, J-P Marie and G Huchon
Leukemia 22: 1361-1367; advance online publication, April 24, 2008; doi:10.1038/leu.2008.100
Chronic Myeloproliferative Disorders
Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia
E Puigdecanet, B Espinet, J J Lozano, L Sumoy, B Bellosillo, L Arenillas, A Álvarez-Larrán, F Solé, S Serrano, C Besses and L Florensa
Leukemia 22: 1368-1376; advance online publication, May 15, 2008; doi:10.1038/leu.2008.112
Minimal Residual Disease
Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial
M Ritgen, S Böttcher, S Stilgenbauer, D Bunjes, J Schubert, S Cohen, A Humpe, M Hallek, M Kneba, N Schmitz, H Döhner and P Dreger
Leukemia 22: 1377-1386; advance online publication, April 17, 2008; doi:10.1038/leu.2008.96
Immunology
HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia
C E Rutten, S A P van Luxemburg-Heijs, M Griffioen, E W A Marijt, I Jedema, M H M Heemskerk, E F M Posthuma, R Willemze and J H F Falkenburg
Leukemia 22: 1387-1394; advance online publication, April 17, 2008; doi:10.1038/leu.2008.90
Sensitivity and Resistance to Therapy
Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment
U Mony, M Jawad, C Seedhouse, N Russell and M Pallis
Leukemia 22: 1395-1401; advance online publication, May 29, 2008; doi:10.1038/leu.2008.125
Oncogenes, Fusion Genes And Tumor suppressor Genes
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
L X Wu, J H Xu, K Z Zhang, Q Lin, X W Huang, C X Wen and Y Z Chen
Leukemia 22: 1402-1409; advance online publication, April 17, 2008; doi:10.1038/leu.2008.89
Myeloma
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo
M A Shammas, H Koley, R C Bertheau, P Neri, M Fulciniti, P Tassone, S Blotta, A Protopopov, C Mitsiades, R B Batchu, K C Anderson, A Chin, S Gryaznov and N C Munshi
Leukemia 22: 1410-1418; advance online publication, May 1, 2008; doi:10.1038/leu.2008.81
VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
M Pineda-Roman, M Zangari, F van Rhee, E Anaissie, J Szymonifka, A Hoering, N Petty, J Crowley, J Shaughnessy, J Epstein and B Barlogie
Leukemia 22: 1419-1427; advance online publication, April 24, 2008; doi:10.1038/leu.2008.99
Letters to the Editor
Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML
H Hasle, J Abrahamsson, M Arola, A Karow, A O'Marcaigh, D Reinhardt, D K H Webb, E van Wering, B Zeller, C M Zwaan and P Vyas
Leukemia 22: 1428-1430; advance online publication, December 6, 2007; doi:10.1038/sj.leu.2405060
Sirolimus enhances the effect of apoptotic cell infusion on hematopoietic engraftment and tolerance induction
F Bonnefoy, E Masson, S Perruche, A Marandin, C Borg, A Radlovic, B Shipman, P Tiberghien, P Saas and F Kleinclauss
Leukemia 22: 1430-1434; advance online publication, December 6, 2007; doi:10.1038/sj.leu.2405061
Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia
P Van Vlierberghe, H B Beverloo, J Buijs-Gladdines, E R van Wering, M Horstmann, R Pieters and J P P Meijerink
Leukemia 22: 1434-1437; advance online publication, December 13, 2007; doi:10.1038/sj.leu.2405063
Induction of Toll-like receptor 2 and 4 expression on CD4+ and CD8+ T cells in G-CSF-mobilized unrelated peripheral blood stem cell grafts during leukapheresis: impact on patient outcome
U Platzbecker, J Stoehlmacher, C Pabst, E Goekkurt, U Oelschlägel, H Schirutschke, K Hölig, C Theuser, U Mogck, G Ehninger and M Bornhäuser
Leukemia 22: 1438-1440; advance online publication, December 13, 2007; doi:10.1038/sj.leu.2405075
MicroRNA expression in lymphocyte development and malignancy
C H Lawrie, N J Saunders, S Soneji, S Palazzo, H M Dunlop, C D O Cooper, P J Brown, X Troussard, H Mossafa, T Enver, F Pezzella, J Boultwood, J S Wainscoat and C S R Hatton
Leukemia 22: 1440-1446; advance online publication, January 10, 2008; doi:10.1038/sj.leu.2405083
Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia
K Stamatopoulos, T Papadaki, C Pontikoglou, I Athanasiadou, N Stavroyianni, J Bux, I Batsis, K Pyrovolaki, G Paterakis, D Anagnostou, A Anagnostopoulos and H A Papadaki
Leukemia 22: 1446-1449; advance online publication, January 10, 2008; doi:10.1038/sj.leu.2405077
Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell
C Nishioka, T Ikezoe, J Yang, H P Koeffler and A Yokoyama
Leukemia 22: 1449-1452; advance online publication, January 10, 2008; doi:10.1038/sj.leu.2405079
Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro
N Brownlow, M Vaid and N J Dibb
Leukemia 22: 1452-1453; advance online publication, January 10, 2008; doi:10.1038/sj.leu.2405085
JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders
N Cambier, A Renneville, T Cazaentre, V Soenen, C Cossement, S Giraudier, N Grardel, J-L Laï, C Rose and C Preudhomme
Leukemia 22: 1454-1455; advance online publication, February 21, 2008; doi:10.1038/sj.leu.2405088
A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL
O G Best, A C Gardiner, A Majid, R Walewska, B Austen, A Skowronska, R Ibbotson, T Stankovic, M J S Dyer and D G Oscier
Leukemia 22: 1456-1459; advance online publication, January 17, 2008; doi:10.1038/sj.leu.2405092
NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?
L Pasqualucci, S Li, G Meloni, S Schnittger, S Gattenlohner, A Liso, M Di Ianni, M P Martelli, E Pescarmona, R Foa, T Haferlach, R C Skoda and B Falini
Leukemia 22: 1459-1463; advance online publication, January 17, 2008; doi:10.1038/sj.leu.2405093
Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia
R Sutton, M Lonergan, H Tapp, N C Venn, M Haber, M D Norris, T A O'Brien, F Alvaro and T Revesz
Leukemia 22: 1463-1465; advance online publication, January 17, 2008; doi:10.1038/sj.leu.2405096
Preclinical targeting of NF-
B and FLT3 pathways in AML cells
E Griessinger, C Frelin, N Cuburu, V Imbert, C Dageville, M Hummelsberger, N Sirvent, M Dreano and J-F Peyron
Leukemia 22: 1466-1469; advance online publication, January 31, 2008; doi:10.1038/sj.leu.2405102
Genomic and molecular switching in relapsed acute promyelocytic leukemia
F Albano, A Pannunzio, L Anelli, A Zagaria, V Liso, M Rocchi and G Specchia
Leukemia 22: 1469-1472; advance online publication, February 7, 2008; doi:10.1038/sj.leu.2405103
